Pharmacy and consumable costs keep climbing — what's actually driving it

Practice owners reviewing supply spend against last year’s numbers are seeing a consistent pattern: pharmacy and consumable costs have climbed faster than general inflation, and the increase isn’t concentrated in one category that’s easy to substitute around — it’s broad-based across generic medications, single-use surgical supplies, and diagnostic test kits.

Where the pressure is coming from

Distributor consolidation has reduced the number of suppliers practices can realistically shop between, which has softened the price competition that used to keep markups in check. On the manufacturing side, several generic veterinary drug categories have seen supply disruptions that pushed practices toward higher-cost alternatives, even temporarily, and pricing on those alternatives hasn’t always come back down once the original product returned to availability.

The categories moving the most

Injectable anesthetics and sedatives, certain antibiotic classes, and single-use surgical consumables (suture, drapes, gloves) are the line items practice owners most commonly flag as moving faster than their fee schedule has kept pace with. Diagnostic test kits — bloodwork panels, in-house assay cartridges — have also seen list-price increases from major manufacturers.

What practices are doing about it

Group purchasing arrangements, where multiple independent practices pool order volume to negotiate distributor pricing, are giving smaller practices leverage closer to what corporate-owned chains get natively. Some practices are also re-shopping their primary distributor relationship for the first time in years, finding that loyalty pricing had quietly fallen behind competitive offers.

Passing cost through without losing clients

Building supply cost trends into an annual fee review — rather than reacting line item by line item as costs move — keeps margins from eroding quietly over several years. Clients generally accept a clearly communicated annual adjustment better than they accept noticing, on their own, that fees haven’t moved while everything else has gotten more expensive.

Bottom line: the cost pressure is structural, not a one-off spike — practices that build it into routine fee review stay ahead of margin erosion; practices that wait to react are absorbing the increase themselves.